{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:15:01Z","timestamp":1792145701639,"version":"4.4.0"},"reference-count":80,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T00:00:00Z","timestamp":1649721600000},"content-version":"vor","delay-in-days":376,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Cardiovascular Interventions"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.jcin.2021.01.040","type":"journal-article","created":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T19:14:32Z","timestamp":1617650072000},"page":"723-738","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Antithrombotic Management of Elderly Patients With Coronary\u00a0Artery\u00a0Disease"],"prefix":"10.1016","volume":"14","author":[{"given":"Piera","family":"Capranzano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominick J.","family":"Angiolillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcin.2021.01.040_bib1","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1161\/CIR.0000000000000659","article-title":"Heart disease and stroke statistics-2019 update: a report from the american heart association","volume":"139","author":"Benjamin","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2021.01.040_bib2","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/j.jacc.2010.04.063","article-title":"Antithrombotic therapy in the elderly","volume":"56","author":"Capodanno","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2021.01.040_bib3","first-page":"3238","article-title":"Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis","volume":"36","author":"Andreotti","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2021.01.040_bib4","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jacc.2019.05.016","article-title":"Management of antithrombotic therapy in atrial fibrillation patients undergoing PCI: JACC state-of-the-art review","volume":"74","author":"Capodanno","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2021.01.040_bib5","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1742-4933-5-12","article-title":"Hemostasis and ageing","volume":"5","author":"Mari","year":"2008","journal-title":"Immun Ageing"},{"key":"10.1016\/j.jcin.2021.01.040_bib6","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.cardiores.2004.12.027","article-title":"Endothelial aging","volume":"66","author":"Brandes","year":"2005","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jcin.2021.01.040_bib7","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1080\/09537104.2019.1665641","article-title":"Modulators of platelet function in aging","volume":"31","author":"Iyer","year":"2020","journal-title":"Platelets"},{"key":"10.1016\/j.jcin.2021.01.040_bib8","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1055\/s-0033-1357506","article-title":"Intracerebral bleeding in patients on antithrombotic agents","volume":"39","author":"Veltkamp","year":"2013","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jcin.2021.01.040_bib9","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1016\/j.jacc.2018.09.057","article-title":"ACC\/AHA versus ESC guidelines on dual antiplatelet therapy: JACC guideline comparison","volume":"72","author":"Capodanno","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2021.01.040_bib10","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1001\/jama.2014.15690","article-title":"Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial","volume":"312","author":"Ikeda","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.jcin.2021.01.040_bib11","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1805819","article-title":"Effect of aspirin on cardiovascular events and bleeding in the healthy elderly","volume":"379","author":"McNeil","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2021.01.040_bib12","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1803955","article-title":"Effect of aspirin on all-cause mortality in the healthy elderly","volume":"379","author":"McNeil","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2021.01.040_bib13","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1056\/NEJMoa1800722","article-title":"Effect of aspirin on disability-free survival in the healthy elderly","volume":"379","author":"McNeil","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2021.01.040_bib14","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.jacc.2019.03.010","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"74","author":"Arnett","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2021.01.040_bib15","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Baigent","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jcin.2021.01.040_bib16","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1046\/j.0306-5251.2001.01476.x","article-title":"Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies","volume":"52","author":"Garc\u00eda Rodr\u00edguez","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jcin.2021.01.040_bib17","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1007\/s11239-019-01933-7","article-title":"Pharmacokinetic\/pharmacodynamic assessment of a novel, pharmaceutical lipid-aspirin complex: results of a randomized, crossover, bioequivalence study","volume":"48","author":"Angiolillo","year":"2019","journal-title":"J\u00a0Thromb Thrombolysis"},{"key":"10.1016\/j.jcin.2021.01.040_bib18","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2021.01.040_bib19","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1093\/eurheartj\/ehr407","article-title":"High on-thienopyridine platelet reactivity in elderly coronary patients: the SENIOR-PLATELET study","volume":"33","author":"Silvain","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2021.01.040_bib20","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.jcin.2019.03.034","article-title":"Updated expert consensus statement on platelet function and genetic testing for guiding P2Y12 receptor inhibitor treatment in percutaneous coronary intervention","volume":"12","author":"Sibbing","year":"2019","journal-title":"J\u00a0Am Coll Cardiol Intv"},{"key":"10.1016\/j.jcin.2021.01.040_bib21","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jcin.2020.01.226","article-title":"Derivation, validation, and prognostic utility of a prediction rule for nonresponse to clopidogrel: the ABCD-GENE score","volume":"13","author":"Angiolillo","year":"2020","journal-title":"J\u00a0Am Coll Cardiol Intv"},{"key":"10.1016\/j.jcin.2021.01.040_bib22","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2021.01.040_bib23","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1177\/0091270009337942","article-title":"Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38","volume":"49","author":"Wrishko","year":"2009","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.jcin.2021.01.040_bib24","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.jacc.2013.05.023","article-title":"Prasugrel 5\u00a0mg in the very elderly attenuates platelet inhibition but maintains noninferiority to prasugrel 10\u00a0mg in nonelderly patients: the GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients","volume":"62","author":"Erlinge","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2021.01.040_bib25","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1161\/CIRCULATIONAHA.113.002303","article-title":"Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel","volume":"128","author":"Roe","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2021.01.040_bib26","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1161\/CIRCULATIONAHA.117.032180","article-title":"Comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization","volume":"137","author":"Savonitto","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2021.01.040_bib27","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/S0140-6736(16)31323-X","article-title":"Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial","volume":"388","author":"Cayla","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jcin.2021.01.040_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2021.01.040_bib29","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1161\/CIRCOUTCOMES.111.964395","article-title":"Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized Platelet Inhibition and Patient Outcomes (PLATO) trial","volume":"5","author":"Husted","year":"2012","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jcin.2021.01.040_bib30","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/S0140-6736(20)30325-1","article-title":"Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial","volume":"395","author":"Gimbel","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jcin.2021.01.040_bib31","article-title":"Efficacy and safety of ticagrelor in comparison to clopidogrel in elderly patients with ST-segment-elevation myocardial infarctions","volume":"8","author":"Schmucker","year":"2019","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jcin.2021.01.040_bib32","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1161\/CIRCULATIONAHA.120.050645","article-title":"Comparison between ticagrelor and clopidogrel in elderly patients with an acute coronary syndrome\u2014insights from the SWEDEHEART registry","volume":"42","author":"Szummer","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2021.01.040_bib33","article-title":"Tailoring P2Y12 inhibiting therapy in elderly patients with myocardial infarction undergoing primary percutaneous coronary intervention","volume":"8","author":"Capranzano","year":"2019","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jcin.2021.01.040_bib34","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1161\/CIRCULATIONAHA.120.050845","article-title":"Ticagrelor or clopidogrel in elderly patients with myocardial infarction: when the choice makes the difference","volume":"142","author":"Capranzano","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2021.01.040_bib35","doi-asserted-by":"crossref","first-page":"436","DOI":"10.7326\/M20-1806","article-title":"Age- and weight-adapted dose of prasugrel versus standard dose of ticagrelor in patients with acute coronary syndromes: results from a randomized trial","volume":"173","author":"Menichelli","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jcin.2021.01.040_bib36","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or 30\u00a0months of dual antiplatelet therapy after drug-eluting stents","volume":"371","author":"Mauri","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2021.01.040_bib37","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2021.01.040_bib38","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa1908077","article-title":"Ticagrelor in patients with stable coronary disease and diabetes","volume":"381","author":"Steg","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2021.01.040_bib39","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.2016.3775","article-title":"Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention","volume":"315","author":"Yeh","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jcin.2021.01.040_bib40","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/s41569-019-0314-y","article-title":"Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease","volume":"17","author":"Capodanno","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jcin.2021.01.040_bib41","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/eurheartj\/ehi485","article-title":"Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients","volume":"27","author":"Andreotti","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2021.01.040_bib42","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2021.01.040_bib43","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2021.01.040_bib44","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/j.jacc.2020.06.085","article-title":"Trial design principles for patients at high bleeding risk undergoing PCI: JACC scientific expert panel","volume":"76","author":"Capodanno","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2021.01.040_bib45","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1161\/CIRCULATIONAHA.120.046308","article-title":"Dual Antiplatelet therapy after percutaneous coronary intervention and drug-eluting stents: a systematic review and network meta-analysis","volume":"142","author":"Khan","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2021.01.040_bib46","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.jcin.2017.11.005","article-title":"To encourage individualized dual antiplatelet therapy duration after drug-eluting stent implantation: a new page of an intriguing book","volume":"11","author":"Gargiulo","year":"2018","journal-title":"J\u00a0Am Coll Cardiol Intv"},{"key":"10.1016\/j.jcin.2021.01.040_bib47","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.jcin.2017.10.015","article-title":"Short-term versus long-term dual antiplatelet therapy after drug-eluting stent implantation in elderly patients: a meta-analysis of individual participant data from 6 randomized trials","volume":"11","author":"Lee","year":"2018","journal-title":"J\u00a0Am Coll Cardiol Intv"},{"key":"10.1016\/j.jcin.2021.01.040_bib48","doi-asserted-by":"crossref","first-page":"78","DOI":"10.4244\/EIJ-D-16-00497","article-title":"Ischaemic and bleeding outcomes in elderly patients undergoing a prolonged versus shortened duration of dual antiplatelet therapy after percutaneous coronary intervention: insights from the PRODIGY randomised trial","volume":"13","author":"Piccolo","year":"2017","journal-title":"EuroIntervention"},{"key":"10.1016\/j.jcin.2021.01.040_bib49","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1161\/CIRCULATIONAHA.117.031164","article-title":"International expert consensus on switching platelet P2Y12 receptor-inhibiting therapies","volume":"136","author":"Angiolillo","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2021.01.040_bib50","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S0140-6736(20)31791-8","article-title":"Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial","volume":"396","author":"Kim","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jcin.2021.01.040_bib51","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/S0140-6736(17)32155-4","article-title":"Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomized, open-label, multicenter trial","volume":"390","author":"Sibbing","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jcin.2021.01.040_bib52","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1093\/eurheartj\/ehy332","article-title":"Age and outcomes following guided de-escalation of antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: results from the randomized TROPICAL-ACS trial","volume":"39","author":"Sibbing","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2021.01.040_bib53","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1907096","article-title":"A\u00a0genotype-guided strategy for oral P2Y12 inhibitors in primary PCI","volume":"381","author":"Claassens","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2021.01.040_bib54","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/s41569-018-0049-1","article-title":"Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention","volume":"15","author":"Capodanno","year":"2018","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jcin.2021.01.040_bib55","article-title":"Safety and efficacy of double antithrombotic therapy with non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation undergoing percutaneous coronary intervention: a systematic review and meta-analysis","volume":"9","author":"Capodanno","year":"2020","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jcin.2021.01.040_bib56","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2021.01.040_bib57","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation","volume":"377","author":"Cannon","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2021.01.040_bib58","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation","volume":"380","author":"Lopes","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2021.01.040_bib59","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0140-6736(19)31872-0","article-title":"Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial","volume":"394","author":"Vranckx","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jcin.2021.01.040_bib60","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.amjcard.2019.11.029","volume":"125","author":"ten Berg","year":"2020","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jcin.2021.01.040_bib61","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1161\/CIRCULATIONAHA.120.050438","article-title":"Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention: a North American perspective: 2021 update","volume":"143","author":"Angiolillo","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2021.01.040_bib62","first-page":"2999","article-title":"2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"32","author":"Collet","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2021.01.040_bib63","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0140-6736(18)31858-0","volume":"392","author":"Vranckx","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jcin.2021.01.040_bib64","doi-asserted-by":"crossref","first-page":"e1605","DOI":"10.4244\/EIJ-D-19-00699","article-title":"Ticagrelor monotherapy beyond one month after PCI in ACS or stable CAD in elderly patients: a pre-specified analysis of the GLOBAL LEADERS trial","volume":"15","author":"Tomaniak","year":"2020","journal-title":"EuroIntervention"},{"key":"10.1016\/j.jcin.2021.01.040_bib65","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1001\/jama.2019.8146","article-title":"Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized clinical trial","volume":"321","author":"Hahn","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jcin.2021.01.040_bib66","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1001\/jama.2019.8145","article-title":"Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial","volume":"321","author":"Watanabe","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jcin.2021.01.040_bib67","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","article-title":"Ticagrelor with or without aspirin in high-risk patients after PCI","volume":"381","author":"Mehran","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2021.01.040_bib68","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1001\/jama.2020.7580","article-title":"Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial","volume":"323","author":"Kim","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jcin.2021.01.040_bib69","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/j.jacc.2019.08.1038","article-title":"Ticagrelor alone versus dual antiplatelet therapy from 1\u00a0month after drug-eluting coronary stenting","volume":"74","author":"Franzone","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2021.01.040_bib70","doi-asserted-by":"crossref","first-page":"627","DOI":"10.4244\/EIJ-D-20-00145","article-title":"Ticagrelor alone or conventional dual antiplatelet therapy in patients with stable or acute coronary syndromes","volume":"16","author":"Franzone","year":"2020","journal-title":"EuroIntervention"},{"key":"10.1016\/j.jcin.2021.01.040_bib71","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1053\/j.gastro.2019.04.041","article-title":"Pantoprazole to prevent gastroduodenal events in patients receiving rivaroxaban and\/or aspirin in a randomized, double-blind, placebo-controlled trial","volume":"157","author":"Moayyedi","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jcin.2021.01.040_bib72","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ijcard.2020.11.065","article-title":"Bleeding risk prediction in elderly patients managed invasively for acute coronary syndromes: external validation of the PRECISE-DAPT and PARIS scores","volume":"328","author":"Montalto","year":"2021","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jcin.2021.01.040_bib73","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1161\/CIRCULATIONAHA.119.040167","article-title":"Defining high bleeding risk in patients undergoing percutaneous coronary intervention","volume":"140","author":"Urban","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2021.01.040_bib74","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1093\/eurheartj\/ehaa671","article-title":"Validation of high bleeding risk criteria and definition as proposed by the academic research consortium for high bleeding risk","volume":"41","author":"Corpataux","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2021.01.040_bib75","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0140-6736(17)30397-5","article-title":"Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials","volume":"389","author":"Costa","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jcin.2021.01.040_bib76","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.0107","article-title":"Outcomes Associated with oral anticoagulants plus antiplatelets in patients with newly diagnosed atrial fibrillation","volume":"3","author":"Fox","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jcin.2021.01.040_bib77","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0140-6736(17)32713-7","article-title":"Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial","volume":"391","author":"Varenne","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jcin.2021.01.040_bib78","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ahj.2018.10.009","article-title":"Design and rationale of the management of high bleeding risk patients post bioresorbable polymer coated stent implantation with an abbreviated versus standard DAPT regimen (MASTER DAPT) study","volume":"209","author":"Frigoli","year":"2019","journal-title":"Am Heart J"},{"key":"10.1016\/j.jcin.2021.01.040_bib79","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.118.004942","article-title":"Association between secondary prevention medication use and outcomes in frail older adults after acute myocardial infarction","volume":"12","author":"Zullo","year":"2019","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jcin.2021.01.040_bib80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ahj.2020.07.005","volume":"228","author":"Li","year":"2020","journal-title":"Am Heart J"}],"updated-by":[{"DOI":"10.1016\/j.jcin.2021.08.017","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T00:00:00Z","timestamp":1633910400000}}],"container-title":["JACC: Cardiovascular Interventions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936879821001862?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936879821001862?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T12:04:58Z","timestamp":1677585898000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936879821001862"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":80,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S1936879821001862"],"URL":"https:\/\/doi.org\/10.1016\/j.jcin.2021.01.040","relation":{},"ISSN":["1936-8798"],"issn-type":[{"value":"1936-8798","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antithrombotic Management of Elderly Patients With Coronary\u00a0Artery\u00a0Disease","name":"articletitle","label":"Article Title"},{"value":"JACC: Cardiovascular Interventions","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcin.2021.01.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}